Clearmind Medicine Announces Patent Application Publication
Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biotech firm dedicated to developing psychedelic-derived therapeutics, has recently published its patent application under the Patent Cooperation Treaty (PCT). This application focuses on innovative combinations of Ketamine and N-Acylethanolamines. This important milestone demonstrates the company’s ongoing commitment to tackling some of the most urgent health challenges in the medical field today.
Collaboration with SciSparc Ltd.
This patent application is a result of a successful partnership between Clearmind and SciSparc Ltd. (Nasdaq: SPRC), a pharmaceutical company that specializes in clinical trials for disorders affecting the central nervous system. Together, they are investigating combination therapies that synergistically blend SciSparc's Palmitoylethanolamide (PEA) with Clearmind's groundbreaking psychedelic molecule, 5-methoxy-2-aminoindan (MEAI). Their goal is to develop effective treatments for addiction, support weight loss, and address a range of mental health disorders.
The Importance of Combination Therapies
So far, this collaboration has led to the filing of thirteen patents with the U.S. Patent and Trademark Office, along with additional applications in various global jurisdictions. This highlights the potential for significant advancements in therapeutic options through these innovative combination therapies.
The Role of the FDA in Ketamine Treatments
Recently, the U.S. Food and Drug Administration approved a ketamine derivative as a nasal spray medication for adult patients suffering from depression, specifically those who haven’t responded to other treatments. This FDA approval underscores the urgent need for effective mental health treatments, especially for patients dealing with major depressive disorder (MDD) who may experience suicidal thoughts or behaviors.
Usage Guidelines and Patient Safety
The approved treatment comes with strict administration guidelines, requiring it to be given only at certified medical facilities and in conjunction with antidepressant medications. Patients must remain at the facility for a two-hour observation period after receiving a dose, allowing healthcare providers to monitor for any serious side effects that may arise.
Comments from Clearmind's CEO
Dr. Adi Zuloff-Shani, CEO of Clearmind, remarked, "Through our collaboration with SciSparc and the extensive research conducted by their team, we have found that combining PEA with various compounds may reduce treatment dosages while still maintaining efficacy and minimizing side effects. Ketamine was approved by the FDA for supervised use due to associated risks, including potential abuse and both psychological and physical dependence. Our ultimate aim is to create safe and effective treatments that deliver therapeutic benefits while reducing adverse reactions."
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical company focused on discovering and developing innovative therapeutics derived from psychedelics. The company aims to tackle prevalent and underserved health issues, such as alcohol use disorder. Clearmind is dedicated to developing compounds from psychedelics with the intention of commercializing them as regulated medicines, food products, or supplements.
Intellectual Property and Future Goals
With a robust intellectual property portfolio that includes nineteen patent families and 29 granted patents, Clearmind is well-positioned to pursue additional patents for its compounds as needed. The company will continue to seek opportunities to acquire more intellectual property to further enhance its portfolio.
About SciSparc Ltd.
SciSparc Ltd. (SPRC) is a clinical-stage pharmaceutical company led by a skilled team of executives and scientists. The company focuses on developing technologies and assets based on cannabinoid pharmaceuticals. Current drug development initiatives include SCI-110 for treating Tourette Syndrome and SCI-210 for addressing autism and status epilepticus, along with a focus on THC and non-psychoactive cannabidiol.
Frequently Asked Questions
What is the focus of Clearmind Medicine?
Clearmind Medicine focuses on the discovery and development of psychedelic-derived therapeutics to address major under-treated health problems.
What is the recent patent application about?
The patent application involves innovative combinations of Ketamine and N-Acylethanolamines aimed at addressing mental health disorders.
Who is Clearmind's collaborator in this patent application?
Clearmind is collaborating with SciSparc Ltd., a company specialized in pharmaceutical treatments for central nervous system disorders.
What are the potential applications of the research?
The research aims to create therapies for addictions, weight loss, and various mental health issues using combination therapies.
How is the FDA involved with Ketamine treatments?
The FDA recently approved a ketamine derivative for treating patients with depression, showcasing a significant step towards effective mental health care.
